SavedAdd your journal

Journals / European Journal of Biology / 2026 / Volume: 84 Issue: 2

Advances in Preclinical Research Models of ROS1 Fusion Proteins in Non-Small Cell Lung Cancer

Yasemin Saygideger(CUKUROVA UNIVERSITY)0000-0003-3293-373X
Taoufik Allababidi(CUKUROVA UNIVERSITY)0009-0000-4936-361X
Pages
—
Publication Date
2025-12-18
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article will be useful for researchers in this field and will help them choose a model that serves their ideas and contributes to the development of appropriate treatments and understanding of changes in the c-ROS1 oncogene.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The rearrangement of ROS proto-oncogene 1 (ROS1, a receptor tyrosine kinase) was first detected in glioblastoma, then recognised in non-small cell lung cancer (NSCLC) in 2007.
📊
Key Findings & Data:These alterations generate fusion proteins, which constitutively activate the kinase domain of ROS1 and hence promote cell prolif eration.
💡
Conclusion & Impact:This article will be useful for researchers in this field and will help them choose a model that serves their ideas and contributes to the development of appropriate treatments and understanding of changes in the c-ROS1 oncogene.
🔬Design:Review & Systematic Survey
📍Scope:2007 Verileri
⚙️Variables:ROS1 fusion · Non-Small-cell lung cancer · Preclinical models

Abstract

The rearrangement of ROS proto-oncogene 1 (ROS1, a receptor tyrosine kinase) was first detected in glioblastoma, then recognised in non-small cell lung cancer (NSCLC) in 2007. These alterations generate fusion proteins, which constitutively activate the kinase domain of ROS1 and hence promote cell prolif eration. NSCLC is the most common type of lung cancer, accounting for approximately 85% of all cases. It is also a very aggressive form of the disease. It is distinguished by genetic differences that affect its biological behaviour and present diverse pathological features. In addition, ROS1 fusions are linked to sensitivity to tyrosine kinase inhibitors, such as crizotinib, which have "off-target" activity against ROS1. Creating new Pre-clinical models, both in vivo and in vitro, that use gene editing and cutting-edge cell culture methods has a huge potential to help make tyrosine kinase inhibitors that are more effective and can target groups of tumours cells that are resistant. Our review focuses on Pre-clinical models developed to date, both in vivo and in vitro, for ROS1+NSCLC and examines their strengths and limitations. This article will be useful for researchers in this field and will help them choose a model that serves their ideas and contributes to the development of appropriate treatments and understanding of changes in the c-ROS1 oncogene.

🔖

Cite This Article

Saygideger, Y., Allababidi, T., *, Y. S. (2025). Advances in Preclinical Research Models of ROS1 Fusion Proteins in Non-Small Cell Lung Cancer. European Journal of Biology, Volume: 84 Issue: 2. https://doi.org/10.26650/EurJBiol.2025.1653778

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (88)

  1. World Health Organization. WHO Fact Sheet on Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed October 20, 2018. google scholar
  2. Li N, Deng Y, Zhou L, et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: Results from the Global Burden of Disease Study 2017. J Hematol Oncol. 2019;12(1):140. doi:10.1186/s13045-019-0828-0 google scholar
  3. Yang X, Tang Z, Li J, Jiang J, Liu Y. Progress of non-small-cell lung cancer with ROS1 rearrangement. Front Mol Biosci. 2023;10:1238093. doi:10.3389/fmolb.2023.1238093 google scholar
  4. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19(49):5548-5557. doi:10.1038/sj.onc.1203957. google scholar
  5. Drilon A, Jenkins C, Iyer S, et al. ROS1-dependent cancers—biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18(1):35-55. google scholar
  6. Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci USA. 1987;84(24):9270-9274. google scholar
  7. Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J Thorac Oncol. 2017;12(11):1611-1625. google scholar
  8. Hung MS, Lin YC, Chen FF, et al. The potential and limitation of targeted chromosomal breakpoint sequencing for the ROS1 fusion gene identification in lung cancer. Am J Cancer Res. 2022;12(5):2376-2386. google scholar
  9. Chin LP, Soo RA, Soong R, Ou SH. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7(11):1625-1630. google scholar
  10. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18(7):865-875. google scholar
  11. Neel DS, Allegakoen DV, Olivas V, et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Res. 2019;79(3):546-556. google scholar
  12. Uddin F, Rudin CM, Sen T. CRISPR gene therapy: Applications, limitations, and implications for the future. Front Oncol. 2020;10:1387. doi:10.3389/fonc.2020.01387 google scholar
  13. Karn V, Sandhya S, Hsu W, et al. CRISPR/Cas9 system in breast cancer therapy: Advancement, limitations and future scope. Cancer Cell Int. 2022;22(1):234. doi:10.1186/s12935-022-02654-3 google scholar
  14. Fus-Kujawa A, Prus P, Bajdak-Rusinek K, et al. An overview of methods and tools for transfection of eukaryotic cells in vitro. Front Bioeng Biotechnol. 2021;9:701031. doi:10.3389/fbioe.2021.701031 google scholar
  15. Meaker GA, Hair EJ, Gorochowski TE. Advances in engineering CRISPR-Cas9 as a molecular Swiss Army knife. Synth Biol (Oxf). 2020;5(1):ysaa021. doi:10.1093/synbio/ysaa021 google scholar
  16. Sinclair F, Begum AA, Dai CC, Toth I, Moyle PM. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing. Drug Deliv Transl Res. 2023;13(5):1500-1519. google scholar
  17. Liu H, Chen W, Li Y, et al. CRISPR/Cas9 technology and its utility for crop improvement. Int J Mol Sci. 2022;23(18):10442. doi:10.3390/ijms231810442 google scholar
  18. Terrones M, Deben C, Rodrigues-Fortes F, et al. CRISPR/Cas9-edited ROS1+ non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles. J Transl Med. 2024;22(1):234. doi:10.1186/s12967-024-04988-0 google scholar
  19. Choi PS, Meyerson M. Targeted genomic rearrangements using CRISPR/Cas technology. Nat Commun. 2014;5:3728. doi:10.1038/ncomms4728 google scholar
  20. Lekomtsev S, Aligianni S, Lapao A, Bürckstümmer T. Efficient generation and reversion of chromosomal translocations using CRISPR/Cas technology. BMC Genomics. 2016;17(1):739. doi:10.1186/s12864-016-3084-5 google scholar
  21. Sato H, Schoenfeld AJ, Siau E, et al. MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions. Clin Cancer Res. 2020;26(12):2932-2945. google scholar
  22. Kim B, Kim Y, Shin S, et al. Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer. Cancer Cell Int. 2022;22(1):82. doi:10.1186/s12935-022-02504-2 google scholar
  23. Qiu XY, Zhu LY, Zhu CS, et al. Highly effective and low-cost microRNA detection with CRISPR-Cas9. ACS Synth Biol. 2018;7(3):807-813. google scholar
  24. Wang R, Zhao X, Chen X, et al. Rolling circular amplification (RCA)-assisted CRISPR/Cas9 cleavage (RACE) for highly specific detection of multiple extracellular vesicle microRNAs. Anal Chem. 2020;92(2):2176-2185. google scholar
  25. Gao Q, Ouyang W, Kang B, et al. Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression. Theranostics. 2020;10(11):5137-5153. google scholar
  26. Yang Y, Xu J, Ge S, Lai L. CRISPR/Cas: Advances, limitations, and applications for precision cancer research. Front Med (Lausanne). 2021;8:649896. doi:10.3389/fmed.2021.649896 google scholar
  27. Yang HC, Chen PJ. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Res. 2018;244:304-310. google scholar
  28. Zischewski J, Fischer R, Bortesi L. Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases. Biotechnol Adv. 2017;35(1):95-104. google scholar
  29. Dubey AK, Mostafavi E. Biomaterials-mediated CRISPR/Cas9 delivery: Recent challenges and opportunities in gene therapy. Front Chem. 2023;11:1259435. doi:10.3389/fchem.2023.1259435 google scholar
  30. Rasul MF, Hussen BM, Salihi A, et al. Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. Mol Cancer. 2022;21(1):64. google scholar
  31. Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene editing to disease treatment in clinics. Precis Clin Med. 2021;4(3):179-191. google scholar
  32. World Health Organization. WHO Fact Sheet on Human Genome Editing. https://www.who.int/publications/i/item/9789240030381. Accessed July 12, 2021. google scholar
  33. Keddy C, Shinde P, Jones K, et al. Resistance profile and structural modeling of next-generation ROS1 tyrosine kinase inhibitors. Mol Cancer Ther. 2022;21(2):336-346. google scholar
  34. Gou W, Zhou X, Liu Z, et al. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib. Cancer Lett. 2018;422:19-28. google scholar
  35. Liu Z, Zhao K, Wei S, et al. ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer. Oncoimmunology. 2020;9(1):1758003. doi:10.1080/2162402X.2020.1758003 google scholar
  36. Deland L, Keane S, Bontell TO, et al. Novel TPR:ROS1 fusion gene activates MAPK, PI3K and JAK/STAT signaling in an infant-type pediatric glioma. Cancer Genomics Proteomics. 2022;19(6):711-726. google scholar
  37. Xu X, Li Y, Xu R, et al. CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells. FEBS J. 2024;291(6):1199-1219. google scholar
  38. Qiao J, Li M, Sun D, Li W, Xin Y. Knockdown of ROS proto-oncogene 1 inhibits migration and invasion in gastric cancer cells by targeting the PI3K/Akt signaling pathway. Onco Targets Ther. 2019;12:8569-8582. google scholar
  39. Katayama R, Gong B, Togashi N, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib-resistant ROS1-G2032R mutation in pre-clinical models. Nat Commun. 2019;10(1):3604. doi:10.1038/s41467-019-11496-z google scholar
  40. Sun R, Meng Y, Xu R, et al. Construction of crizotinib-resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy. Cell Signal. 2023;101:110497. doi:10.1016/j.cellsig.2022.110497 google scholar
  41. Iyer SR, Nusser K, Jones K, et al. Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. EMBO Mol Med. 2023;15(10):e17367. doi:10.15252/emmm.202217367 google scholar
  42. Thawani R, Repetto M, Keddy C, et al. TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers. NPJ Precis Oncol. 2024;8(1):175. doi:10.1038/s41698-024-00663-1 google scholar
  43. Cai L, Duan J, Qian L, et al. ROS1 fusion mediates immunogenicity by upregulation of PD-L1 after the activation of ROS1-SHP2 signaling pathway in non-small cell lung cancer. Front Immunol. 2020;11:527750. doi:10.3389/fimmu.2020.527750 google scholar
  44. Chong Z, Yeap S, Ho W. Transfection types, methods and strategies: A technical review. PeerJ. 2021;9:e11165. doi:10.7717/peerj.11165 google scholar
  45. Duckert B, Vinkx S, Braeken D, Fauvart M. Single-cell transfection technologies for cell therapies and gene editing. J Control Release. 2021;330:963-975. google scholar
  46. Gupta AK, Gupta UD. Next generation sequencing and its applications. In: Verma AS, Singh A, eds. Animal Biotechnology. 1st ed. Amsterdam, Netherlands: Academic Press; 2014:345-367. google scholar
  47. Yun MR, Kim DH, Kim SY, et al. Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front-mutant ROS1-rearranged non-small cell lung cancer. Clin Cancer Res. 2020;26(13):3287-3295. google scholar
  48. Riccardo F, Barutello G, Petito A, et al. Immunization against ROS1 by DNA electroporation impairs K-Ras-driven lung adenocarcinomas. Vaccines (Basel). 2020;8(2):166. doi:10.3390/vaccines8020166 google scholar
  49. Lundin A, Porritt MJ, Jaiswal H, et al. Development of an ObLiGaRe doxycycline-inducible Cas9 system for pre-clinical cancer drug discovery. Nat Commun. 2020;11(1):4903. doi:10.1038/s41467-020-18548-9 google scholar
  50. Arai Y, Totoki Y, Takahashi H, et al. Mouse model for ROS1-rearranged lung cancer. PLoS One. 2013;8(2):e56010. doi:10.1371/journal.pone.0056010 google scholar
  51. Terrones M, Deben C, Rodrigues-Fortes F, et al. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles. J Transl Med. 2024;22(1):234. doi:10.1186/s12967-024-04988-0 google scholar
  52. Mengstie MA. Viral vectors for the in vivo delivery of CRISPR components: Advances and challenges. Front Bioeng Biotechnol. 2022;10:895713. doi:10.3389/fbioe.2022.895713 google scholar
  53. Inoue M, Toki H, Matsui J, et al. Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency. Carcinogenesis. 2016;37(5):452-460. google scholar
  54. Rijmers J, Bui V, van Heijningen C, et al. TRSC-06 characterization of a nonsmall cell lung cancer ROS1-fusion brain metastasis model. Neurooncol Adv. 2024;6(Suppl 1):i40-i41. doi:10.1093/noajnl/vdae090.134 google scholar
  55. Blasco R, Karaca E, Ambrogio C, et al. Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 2014;9(4):1219-1227. google scholar
  56. Zou H, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA. 2015;112(11):3493-3498. google scholar
  57. Bourré L. Genetically engineered or syngeneic mouse models? Crown Bioscience website. Accessed July 3, 2025. google scholar
  58. Barbeau J. Genetically engineered mouse models (GEMM) for I/O studies - Crown Bioscience. Accessed July 3, 2025. google scholar
  59. Abdolahi S, Ghazvinian Z, Muhammadnejad S, et al. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022;20:206. doi:10.1186/s12967-022-03405-8 google scholar
  60. Ruzzi F, Angelicola S, Landuzzi L, et al. ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: A novel preclinical model for new drug development of ROS1-rearranged NSCLC. Transl Lung Cancer Res. 2022;11(11):2216-2229. google scholar
  61. Drilon A, Horan JC, Tangpeerachaikul A, et al. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer Discov. 2023;13(3):598-615. google scholar
  62. Kato Y, Ninomiya K, Ohashi K, et al. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. Cancer Sci. 2018;109(10):3149-3158. google scholar
  63. Lin JJ, Langenbucher A, Gupta P, et al. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis Oncol. 2020;4:21. google scholar
  64. Xu C, Li X, Liu P, Li M, Luo F. Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine. Oncol Lett. 2019;17(1):3-10. google scholar
  65. Howle R, Moorthy A, Buggy DJ. Investigating the influence of anaesthesiology for cancer resection surgery on oncologic outcomes: The role of experimental in vivo models. Medicina (Kaunas). 2022;58(10):1380. doi:10.3390/medicina58101380 google scholar
  66. Chulpanova D, Kitaeva K, Rutland C, et al. Mouse tumor models for advanced cancer immunotherapy. Int J Mol Sci. 2020;21(11):4118. doi:10.3390/ijms21114118 google scholar
  67. Yang Y, Yang H, Hu Y, et al. Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget. 2017;8(19):30621-30643. google scholar
  68. Saborowski A, Saborowski M, Davare MA, et al. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci USA. 2013;110(48):19513-19518. google scholar
  69. Davare MA, Saborowski A, Eide CA, et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci USA. 2013;110(48):19519-19524. google scholar
  70. Tian Q, Zhang Z, Tan L, et al. Skin and heart allograft rejection solely by long-lived alloreactive TRM cells in skin of severe combined immunodeficient mice. Sci Adv. 2022;8(4):eabk0270. doi:10.1126/sciadv.abk0270 google scholar
  71. Chen P, Yao F, Lu Y, et al. Single-cell landscape of mouse islet allograft and syngeneic graft. Front Immunol. 2022;13:853349. doi:10.3389/fimmu.2022.853349 google scholar
  72. Chaudhary K, Mishra N. A review on molecular docking: Novel tool for drug discovery. JSM Chem. 2016;4(3):1029. doi:10.47739/2334-1831/1029 google scholar
  73. Luo LX, Fan XX, Li Y, et al. Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells. Med Chem Comm. 2017;8(3):621-624. google scholar
  74. Younus S, et al. Docking and dynamic simulation study of crizotinib and temozolomide drug with glioblastoma and NSCLC target to identify better efficacy of the drug. Future J Pharm Sci. 2021;7:Article 1. doi:10.1186/s43094-021-00231-7 google scholar
  75. Zhao X, Zhang X, Chen H, et al. Mechanisms of resistance to tyrosine kinase inhibitors in ROS1 fusion-positive nonsmall cell lung cancer. Clin Chem. 2024;70(4):629-641. google scholar
  76. Nisius B, Sha F, Gohlke H. Structure-based computational analysis of protein binding sites for function and druggability prediction. J Biotechnol. 2012;159(3):123-134. google scholar
  77. Bubendorf L, Büttner R, Al-Dayel F, et al. Testing for ROS1 in non-small cell lung cancer: A review with recommendations. Virchows Arch. 2016;469(5):489-503. google scholar
  78. Cao B, Wei P, Liu Z, et al. Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther. 2015;9:131-138. google scholar
  79. Selinger CI, Li BT, Pavlakis N, et al. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Histopathology. 2017;70(3):402-411. google scholar
  80. Morris TA, Khoo C, Solomon BJ. Targeting ROS1 rearrangements in non-small cell lung cancer: Crizotinib and newer generation tyrosine kinase inhibitors. Drugs. 2019;79(12):1277-1286. google scholar
  81. Viola P, Maurya M, Croud J, et al. A validation study for the use of ROS1 immunohistochemical staining in screening for ROS1 translocations in lung cancer. J Thorac Oncol. 2016;11(7):1029-1039. google scholar
  82. Narine N, Wallace A, Dore J, et al. Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital. Cytopathology. 2021;32(5):621-630. google scholar
  83. Takeda M, Sakai K, Terashima M, et al. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. Ann Oncol. 2015;26(12):2477-2482. google scholar
  84. Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res. 2015;21(16):3631-3639. google scholar
  85. Peled N, Palmer G, Hirsch FR, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7(9):e14-e16. google scholar
  86. Terrones M, de Beeck KO, Van Camp G, Vandeweyer G. Pre-clinical modelling of ROS1+ non-small cell lung cancer. Lung Cancer. 2023;180:107192. doi:10.1016/j.lungcan.2023.107192 google scholar
  87. Terrones M, Deben C, Rodrigues-Fortes F, et al. CRISPR/Cas9-edited ROS1+ nonsmall cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles. J Transl Med. 2024;22(1):234. doi:10.1186/s12967-024-04988-0 google scholar
  88. Muminovic M, Carracedo Uribe CR, Alvarez-Pinzon A, Shan K, Raez LE. Importance of ROS1 gene fusions in non-small cell lung cancer. Cancer Drug Resist. 2023;6(2):332-344. google scholar